Investigational Drug Details
| Drug ID: | D311 |
| Drug Name: | Fenofibrate |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01039 |
| DrugBank Description: | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585] |
| PubChem ID: | 3339 |
| CasNo: | 49562-28-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1 |
| Structure: |
|
| InChiKey: | YMTINGFKWWXKFG-UHFFFAOYSA-N |
| Molecular Weight: | 360.831 |
| DrugBank Targets: | Peroxisome proliferator-activated receptor alpha; Nuclear receptor subfamily 1 group I member 2; Matrix metalloproteinase-25 |
| DrugBank MoA: | Fenofibrate activates peroxisome proliferator activated receptor alpha (PPARα), increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III.[A186002,L8588,L8591] PPARα is a nuclear receptor and its activation alters lipid, glucose, and amino acid homeostasis.[A186002] Activation of PPARα activates transcription of gene transcription and translation that generates peroxisomes filled with hydrogen peroxide, reactive oxygen species, and hydroxyl radicals that also participate in lipolysis.[A186005] This mechanism of increased lipid metabolism is also associated with increased oxidative stress on the liver.[A186005] In rare cases this stress can lead to cirrhosis and chronic active hepatitis.[A186002,L8588,L8591] |
| DrugBank Pharmacology: | Fenofibrate is a fibrate that activates peroxisome proliferator activated receptor alpha (PPARα) to alter lipid metabolism and treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.[A186002,L8588,L8591] Fenofibrate requires once daily dosing and has a half life of 19-27 hours so its duration of action is long.[A36366,L8588,L8591] Fenofibrate capsules are given at a dose of 50-150mg daily so the therapeutic index is wide.[L8591] Patients should be counselled about the risk of rhabdomyolysis, myopathy, and cholelithiasis when taking fibrates.[L8588,L8591] |
| DrugBank Indication: | Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L4771 | NCT00832390 | PHASE4 | COMPLETED | YES | 2007-02-14 | 2017-05-30 | Details |
| L5198 | NCT00306384 | PHASE3 | COMPLETED | YES | 2006-03 | 2013-03-22 | Details |
| L5284 | NCT02655770 | PHASE4 | COMPLETED | NO | 2016-02 | 2021-01-14 | Details |
| L5533 | NCT01478399 | PHASE1 | COMPLETED | NO | 2011-12 | 2013-04-15 | Details |
| L5580 | NCT01099137 | PHASE4 | COMPLETED | NO | 2010-01 | 2014-05-28 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|